198 related articles for article (PubMed ID: 27514658)
1. ESR1, ERBB2, and Ki67 mRNA expression predicts stage and grade of non-muscle-invasive bladder carcinoma (NMIBC).
Breyer J; Wirtz RM; Laible M; Schlombs K; Erben P; Kriegmair MC; Stoehr R; Eidt S; Denzinger S; Burger M; Hartmann A; Otto W
Virchows Arch; 2016 Nov; 469(5):547-552. PubMed ID: 27514658
[TBL] [Abstract][Full Text] [Related]
2. ERBB2 Expression as Potential Risk-Stratification for Early Cystectomy in Patients with pT1 Bladder Cancer and Concomitant Carcinoma in situ.
Breyer J; Otto W; Wirtz RM; Wullich B; Keck B; Erben P; Kriegmair MC; Stoehr R; Eckstein M; Laible M; Schlombs K; Eidt S; Denzinger S; Burger M; Hartmann A;
Urol Int; 2017; 98(3):282-289. PubMed ID: 27992871
[TBL] [Abstract][Full Text] [Related]
3. Technical validation of an RT-qPCR in vitro diagnostic test system for the determination of breast cancer molecular subtypes by quantification of ERBB2, ESR1, PGR and MKI67 mRNA levels from formalin-fixed paraffin-embedded breast tumor specimens.
Laible M; Schlombs K; Kaiser K; Veltrup E; Herlein S; Lakis S; Stöhr R; Eidt S; Hartmann A; Wirtz RM; Sahin U
BMC Cancer; 2016 Jul; 16():398. PubMed ID: 27389414
[TBL] [Abstract][Full Text] [Related]
4. An international reproducibility study validating quantitative determination of ERBB2, ESR1, PGR, and MKI67 mRNA in breast cancer using MammaTyper®.
Varga Z; Lebeau A; Bu H; Hartmann A; Penault-Llorca F; Guerini-Rocco E; Schraml P; Symmans F; Stoehr R; Teng X; Turzynski A; von Wasielewski R; Gürtler C; Laible M; Schlombs K; Joensuu H; Keller T; Sinn P; Sahin U; Bartlett J; Viale G
Breast Cancer Res; 2017 May; 19(1):55. PubMed ID: 28490348
[TBL] [Abstract][Full Text] [Related]
5. Comparison of immunohistochemistry with PCR for assessment of ER, PR, and Ki-67 and prediction of pathological complete response in breast cancer.
Sinn HP; Schneeweiss A; Keller M; Schlombs K; Laible M; Seitz J; Lakis S; Veltrup E; Altevogt P; Eidt S; Wirtz RM; Marmé F
BMC Cancer; 2017 Feb; 17(1):124. PubMed ID: 28193205
[TBL] [Abstract][Full Text] [Related]
6. ESR1, PGR, ERBB2, and MKi67 mRNA expression in postmenopausal women with hormone receptor-positive early breast cancer: results from ABCSG Trial 6.
Filipits M; Rudas M; Singer CF; Fitzal F; Bago-Horvath Z; Greil R; Balic M; Lax SF; Halper S; Hulla W; Wu NC; Liu X; Weidler J; Bates M; Hlauschek D; Gnant M; Dubsky P
ESMO Open; 2021 Aug; 6(4):100228. PubMed ID: 34371382
[TBL] [Abstract][Full Text] [Related]
7. Predictive value of molecular subtyping in NMIBC by RT-qPCR of ERBB2, ESR1, PGR and MKI67 from formalin fixed TUR biopsies.
Breyer J; Wirtz RM; Otto W; Laible M; Schlombs K; Erben P; Kriegmair MC; Stoehr R; Eidt S; Denzinger S; Burger M; Hartmann A
Oncotarget; 2017 Sep; 8(40):67684-67695. PubMed ID: 28978063
[TBL] [Abstract][Full Text] [Related]
8. Comparison of immunohistochemistry and RT-qPCR for assessing ER, PR, HER2, and Ki67 and evaluating subtypes in patients with breast cancer.
Chen L; Chen Y; Xie Z; Luo J; Wang Y; Zhou J; Huang L; Li H; Wang L; Liu P; Shu M; Zhang W; Ke Z
Breast Cancer Res Treat; 2022 Aug; 194(3):517-529. PubMed ID: 35789315
[TBL] [Abstract][Full Text] [Related]
9. Robustness of biomarker determination in breast cancer by RT-qPCR: impact of tumor cell content, DCIS and non-neoplastic breast tissue.
Hartmann K; Schlombs K; Laible M; Gürtler C; Schmidt M; Sahin U; Lehr HA
Diagn Pathol; 2018 Oct; 13(1):83. PubMed ID: 30342538
[TBL] [Abstract][Full Text] [Related]
10. Comparison of central laboratory assessments of ER, PR, HER2, and Ki67 by IHC/FISH and the corresponding mRNAs (ESR1, PGR, ERBB2, and MKi67) by RT-qPCR on an automated, broadly deployed diagnostic platform.
Wu NC; Wong W; Ho KE; Chu VC; Rizo A; Davenport S; Kelly D; Makar R; Jassem J; Duchnowska R; Biernat W; Radecka B; Fujita T; Klein JL; Stonecypher M; Ohta S; Juhl H; Weidler JM; Bates M; Press MF
Breast Cancer Res Treat; 2018 Nov; 172(2):327-338. PubMed ID: 30120700
[TBL] [Abstract][Full Text] [Related]
11. FOXM1 overexpression is associated with adverse outcome and predicts response to intravesical instillation therapy in stage pT1 non-muscle-invasive bladder cancer.
Breyer J; Wirtz RM; Erben P; Rinaldetti S; Worst TS; Stoehr R; Eckstein M; Sikic D; Denzinger S; Burger M; Hartmann A; Otto W
BJU Int; 2019 Jan; 123(1):187-196. PubMed ID: 30120861
[TBL] [Abstract][Full Text] [Related]
12. Biological subtyping of early breast cancer: a study comparing RT-qPCR with immunohistochemistry.
Wirtz RM; Sihto H; Isola J; Heikkilä P; Kellokumpu-Lehtinen PL; Auvinen P; Turpeenniemi-Hujanen T; Jyrkkiö S; Lakis S; Schlombs K; Laible M; Weber S; Eidt S; Sahin U; Joensuu H
Breast Cancer Res Treat; 2016 Jun; 157(3):437-46. PubMed ID: 27220750
[TBL] [Abstract][Full Text] [Related]
13. The detection of ESR1/PGR/ERBB2 mRNA levels by RT-QPCR: a better approach for subtyping breast cancer and predicting prognosis.
Du X; Li XQ; Li L; Xu YY; Feng YM
Breast Cancer Res Treat; 2013 Feb; 138(1):59-67. PubMed ID: 23397283
[TBL] [Abstract][Full Text] [Related]
14. In stage pT1 non-muscle-invasive bladder cancer (NMIBC), high KRT20 and low KRT5 mRNA expression identify the luminal subtype and predict recurrence and survival.
Breyer J; Wirtz RM; Otto W; Erben P; Kriegmair MC; Stoehr R; Eckstein M; Eidt S; Denzinger S; Burger M; Hartmann A;
Virchows Arch; 2017 Mar; 470(3):267-274. PubMed ID: 28074276
[TBL] [Abstract][Full Text] [Related]
15. High PDL1 mRNA expression predicts better survival of stage pT1 non-muscle-invasive bladder cancer (NMIBC) patients.
Breyer J; Wirtz RM; Otto W; Erben P; Worst TS; Stoehr R; Eckstein M; Denzinger S; Burger M; Hartmann A
Cancer Immunol Immunother; 2018 Mar; 67(3):403-412. PubMed ID: 29150702
[TBL] [Abstract][Full Text] [Related]
16. High expression of ERBB2 is an independent risk factor for reduced recurrence-free survival in patients with stage T1 non-muscle-invasive bladder cancer.
Sikic D; Eckstein M; Weyerer V; Kubon J; Breyer J; Roghmann F; Kunath F; Keck B; Erben P; Hartmann A; Wirtz RM; Wullich B; Taubert H; Wach S
Urol Oncol; 2022 Feb; 40(2):63.e9-63.e18. PubMed ID: 34330652
[TBL] [Abstract][Full Text] [Related]
17. FOXM1 predicts disease progression in non-muscle invasive bladder cancer.
Rinaldetti S; Wirtz R; Worst TS; Hartmann A; Breyer J; Dyrskjot L; Erben P
J Cancer Res Clin Oncol; 2018 Sep; 144(9):1701-1709. PubMed ID: 29959570
[TBL] [Abstract][Full Text] [Related]
18. Macrodissection prior to closed system RT-qPCR is not necessary for estrogen receptor and HER2 concordance with IHC/FISH in breast cancer.
Gupta S; Mani NR; Carvajal-Hausdorf DE; Bossuyt V; Ho K; Weidler J; Wong W; Rhees B; Bates M; Rimm DL
Lab Invest; 2018 Aug; 98(8):1076-1083. PubMed ID: 29858579
[TBL] [Abstract][Full Text] [Related]
19. Reliable PCR quantitation of estrogen, progesterone and ERBB2 receptor mRNA from formalin-fixed, paraffin-embedded tissue is independent of prior macro-dissection.
Tramm T; Hennig G; Kyndi M; Alsner J; Sørensen FB; Myhre S; Sørlie T; Overgaard J
Virchows Arch; 2013 Dec; 463(6):775-86. PubMed ID: 24100522
[TBL] [Abstract][Full Text] [Related]
20. Clinical relevance of Ki67 gene expression analysis using formalin-fixed paraffin-embedded breast cancer specimens.
Yamamoto S; Ibusuki M; Yamamoto Y; Fu P; Fujiwara S; Murakami K; Iwase H
Breast Cancer; 2013 Jul; 20(3):262-70. PubMed ID: 22362219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]